Results 131 to 140 of about 7,647,352 (298)

Hadronic production of $Ξ_{cc}$ at a fixed-target experiment at the LHC

, 2014
In the paper, we present a detailed discussion on the $Ξ_{cc}$ production at a fixed target experiment at the LHC (After@LHC). The doubly charmed baryon $Ξ_{cc}$ is produced via the channel, ${\rm Proton} + {\rm Proton}\toΞ_{cc}+X$. In estimating its hadroproduction, we discuss three dominant subprocesses, e.g.
Chen, Gu, Wu, Xing-Gang, Zhang, Jia-Wei, Han, Hua-Yong, Fu, Hai-Bing   +4 more
openaire   +2 more sources

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

Fixed target issues for the Tevatron Upgrade

, 1988
The Tevatron Upgrade poses some interesting prospects for the Fixed-Target program if an option to extract the high energy proton beam is preserved. This paper presents a summary of the advantages of increased energy for fixed target experiments, and ...
Stefanski, R.
core   +1 more source

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

The D-optimal design of blocked and split-plot experiments with mixture components. [PDF]

So far, the optimal design of blocked and split-plot experiments involving mixture components has received scant attention. In this paper, an easy method to construct efficient blocked mixture experiments in the presence of fixed and/or random blocks is ...
Goos, Peter, Donev, AN
core  

Characterization of the PADME positron beam for the X17 measurement

Journal of High Energy Physics
This paper presents a detailed characterization of the positron beam delivered by the Beam Test Facility at Laboratori Nazionali of Frascati to the PADME experiment during Run III, which took place from October to December 2022.
The PADME collaboration, S. Bertelli, F. Bossi, B. Buonomo, R. De Sangro, C. Di Giulio, E. Di Meco, K. Dimitrova, D. Domenici, F. Ferrarotto, G. Finocchiaro, L. G. Foggetta, A. Frankenthal, M. Garattini, G. Georgiev, P. Gianotti, S. Ivanov, Sv. Ivanov, V. Kozhuharov, E. Leonardi, E. Long, M. Mancini, G. C. Organtini, M. Raggi, I. Sarra, R. Simeonov, T. Spadaro, E. Spiriti, P. Valente, A. Variola, E. Vilucchi   +30 more
doaj   +1 more source

Production of Open and Hidden Charm in Fixed-target Experiments at the LHC

Acta Physica Polonica B Proceedings Supplement
We discuss the production of \(D\) mesons and \(J/\psi \) quarkonia in proton–nucleus collisions in the fixed-target LHCb experiment. We consider gluon–gluon fusion within \(k_{\mathrm {t}}\)-factorization, processes initiated by intrinsic charm in the nucleon and perturbative recombination mechanism. All the mechanisms seem to be necessary to describe
A. Szczurek, A. Cisek, R. Maciuła
openaire   +2 more sources

Transcriptional profiling of circulating extracellular vesicles from prebiopsy prostate cancer patients

Molecular Oncology, EarlyView.
RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner, Pierre Tennstedt, Randi C. Pose, Christian Müller, Katharina Besler, Svenja Schneegans, Malik Alawi, Marie C. Roesch, Sven Peine, Desiree Bonci, Joanna Budna‐Tukan, Evi Lianidou, Catherine Alix‐Panabières, Derya Tilki, Klaus Pantel   +14 more
wiley   +1 more source

Production of Λ hyperons in 4.0A GeV and 4.5A GeV carbon-nucleus interactions at the Nuclotron

Journal of High Energy Physics
The BM@N experiment (Baryonic Matter at the Nuclotron) is the first fixed-target experiment at the JINR NICA accelerator complex. In this work, data on the interactions of a carbon-ion beam with kinetic energies of 4.0A GeV and 4.5A GeV with C, Al, Cu ...
The BM@N collaboration, S. Afanasiev, G. Agakishiev, A. Aleksandrov, E. Aleksandrov, I. Aleksandrov, P. Alekseev, K. Alishina, V. Astakhov, T. Aushev, V. Azorskiy, V. Babkin, N. Balashov, R. Barak, A. Baranov, D. Baranov, N. Baranova, N. Barbashina, S. Bazylev, M. Belov, D. Blau, V. Bocharnikov, G. Bogdanova, E. Bondar, E. Boos, E. Bozorov, M. Buryakov, S. Buzin, A. Chebotov, D. Chemezov, J. H. Chen, A. Demanov, D. Dementev, A. Dmitriev, J. Drnoyan, D. Dryablov, B. Dubinchik, P. Dulov, A. Egorov, D. Egorov, V. Elsha, A. Eviev, A. Fediunin, A. Fedosimova, I. Filippov, I. Filozova, D. Finogeev, I. Gabdrakhmanov, O. Gavrischuk, K. Gertsenberger, O. Golosov, V. Golovatyuk, P. Grigoriev, M. Golubeva, F. Guber, S. Ibraimova, D. Idrisov, T. Idrissova, A. Iusupova, A. Ivashkin, A. Izvestnyy, V. Kabadzhov, A. Kakhorova, Sh. Kanokova, M. Kapishin, V. Karjavin, D. Karmanov, N. Karpushkin, R. Kattabekov, V. Kekelidze, S. Khabarov, P. Kharlamov, G. Khudaiberdyev, Yu. Kiryushin, P. Klimai, V. Kolesnikov, A. Kolozhvari, V. Kondratiev, Yu. Kopylov, M. Korolev, L. Kovachev, I. Kovalev, I. Kruglova, V. Kozlov, S. Kuklin, E. Kulish, A. Kurganov, V. Kutergina, A. Kuznetsov, E. Ladygin, D. Lanskoy, N. Lashmanov, I. Lebedev, V. Lenivenko, R. Lednický, V. Leontiev, E. Litvinenko, D. Lyapin, Y. G. Ma, A. Makankin, A. Makhnev, A. Malakhov, M. Mamaev, A. Martemianov, M. Merkin, S. Merts, S. Morozov, Yu. Murin, K. Musaev, G. Musulmanbekov, D. Myktybekov, R. Nagdasev, S. Nemnyugin, D. Nikitin, R. Nizamov, S. Novozhilov, A. Olimov, Kh. Olimov, K. Olimov, I. Osokin, V. Palichik, P. Parfenov, I. Pelevanyuk, D. Peresunko, S. Piyadin, M. Platonova, V. Plotnikov, D. Podgainy, I. Polev, I. Pshenichnov, N. Pukhaeva, F. Ratnikov, S. Reshetova, V. Rogov, I. Romanov, I. Rufanov, P. Rukoyatkin, M. Rumyantsev, T. Rybakov, D. Sakulin, S. Sedykh, S. Savenkov, D. Serebryakov, A. Shabanov, S. Sergeev, A. Serikkanov, A. Sheremetev, A. Sheremeteva, A. Shchipunov, M. Shitenkov, M. Shodmonov, M. Shopova, A. Shutov, V. Shutov, I. Slepnev, V. Slepnev, I. Slepov, A. Smirnov, A. Solomin, A. Sorin, V. Spaskov, A. Stavinskiy, V. Stekhanov, Yu. Stepanenko, E. Streletskaya, O. Streltsova, M. Strikhanov, E. Sukhov, D. Suvarieva, A. Svetlichnyi, G. Taer, A. Taranenko, N. Tarasov, O. Tarasov, P. Teremkov, A. Terletsky, O. Teryaev, V. Tcholakov, V. Tikhomirov, A. Timoshenko, O. Tojiboev, N. Topilin, T. Tretyakova, V. Troshin, A. Truttse, I. Tserruya, V. Tskhay, I. Tyapkin, V. Ustinov, V. Vasendina, V. Velichkov, K. Vitanov, N. Vitanov, V. Volkov, A. Voronin, A. Voronin, N. Voytishin, B. Yuldashev, V. Yurevich, N. Zamiatin, M. Zavertyaev, S. Zhang, I. Zhavoronkova, V. Zhezher, N. Zhigareva, I. Zhironkin, A. Zinchenko, R. Zinchenko, A. Zubankov, E. Zubarev, M. Zuev   +210 more
doaj   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source